Loading...
XTSE
HLS
Market cap112mUSD
Jul 09, Last price  
4.87CAD
1D
-0.20%
1Q
21.14%
Name

HLS Therapeutics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
1.99
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.63%
Rev. gr., 5y
0.89%
Revenues
57m
-10.23%
68,202,16949,661,118100,588,71068,147,08271,875,65688,098,90478,746,327116,555,59279,465,98773,877,12519,956,00054,031,00075,082,00061,415,00054,160,00056,109,00060,009,00061,467,00063,074,00056,619,000
Net income
-20m
L-28.61%
9,507,4901,310,0547,594,66802,553,719011,983,34916,867,2039,732,61812,717,29500-6,097,000-24,806,000-19,552,000-15,331,000-13,117,000-23,598,000-27,531,000-19,655,000
CFO
8m
-49.31%
12,500,430703,50021,977,1785,554,6425,323,27325,063,98917,918,70721,230,76318,031,12418,208,9140027,166,00032,747,00026,408,0009,344,00016,429,00016,942,00015,789,0008,003,000
Dividend
Apr 27, 20230.05 CAD/sh
Earnings
Aug 06, 2025

Profile

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.
URL
https://www.hlstherapeutics.com/
IPO date
Mar 17, 1980
Employees
99
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
56,619
-10.23%
63,074
2.61%
61,467
2.43%
Cost of revenue
35,925
35,910
40,562
Unusual Expense (Income)
NOPBT
20,694
27,164
20,905
NOPBT Margin
36.55%
43.07%
34.01%
Operating Taxes
4,073
(272)
(124)
Tax Rate
19.68%
NOPAT
16,621
27,436
21,029
Net income
(19,655)
-28.61%
(27,531)
16.67%
(23,598)
79.90%
Dividends
(2,398)
(4,962)
Dividend yield
1.88%
1.56%
Proceeds from repurchase of equity
(600)
(1,552)
(998)
BB yield
0.48%
1.22%
0.31%
Debt
Debt current
5,284
5,156
13,584
Long-term debt
62,048
83,349
84,771
Deferred revenue
Other long-term liabilities
778
2,210
817
Net debt
49,876
66,553
77,632
Cash flow
Cash from operating activities
8,003
15,789
16,942
CAPEX
(15)
(41)
(10,148)
Cash from investing activities
11,735
(189)
(10,148)
Cash from financing activities
(23,364)
(14,639)
(6,856)
FCF
16,646
32,751
22,932
Balance
Cash
17,456
21,952
20,723
Long term investments
Excess cash
14,625
18,798
17,650
Stockholders' equity
56,205
83,832
111,497
Invested Capital
123,944
168,730
205,830
ROIC
11.36%
14.65%
9.39%
ROCE
14.51%
14.49%
9.33%
EV
Common stock shares outstanding
31,839
32,263
32,433
Price
3.93
-0.51%
3.95
-59.82%
9.83
-34.47%
Market cap
125,129
-1.81%
127,440
-60.03%
318,815
-33.96%
EV
175,005
193,993
396,447
EBITDA
43,411
59,103
55,307
EV/EBITDA
4.03
3.28
7.17
Interest
10,083
8,748
7,317
Interest/NOPBT
48.72%
32.20%
35.00%